Deep Track Capital PYXS Position
Exited4-Fund ConvergenceDeep Track Capital exited their position in Pyxis Oncology, Inc. (PYXS) in Q4 2024, after holding the stock for 4 quarters.
The position was first reported in Q1 2024 and has been tracked across 4 quarterly 13F filings.
PYXS is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
4.8%
8.3 days to cover
Deep Track Capital PYXS Position History
Frequently Asked Questions
Does Deep Track Capital own PYXS?
No. Deep Track Capital exited their position in Pyxis Oncology, Inc. (PYXS) in Q4 2024. They previously held the stock for 4 quarters.
How many hedge funds own PYXS?
4 specialist biotech hedge funds currently hold PYXS, including Tang Capital Management, Perceptive Advisors, Cormorant Asset Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy PYXS?
Deep Track Capital's position in PYXS was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's PYXS position increasing or decreasing?
Deep Track Capital completely exited their PYXS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PYXSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →